Company Profile

Oasis Pharmaceuticals LLC
Profile last edited on: 2/11/2023      CAGE: 6G7D5      UEI: F2ZWBFV5NZ86

Business Identifier: Novel liver disease treat
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

64 Fifer Lane
Lexington, MA 02420
   (617) 766-3915
Location: Multiple
Congr. District: 05
County: Middlesex

Public Profile

Oasis Pharmaceutical is structured around advancing novel treatments meaningfully to improve the health of patients with inflammatory, fibrotic, and metabolic disorders by targeting the G-protein coupled receptor (GPCR) Protease-activated Receptor 2 (PAR2). Anchored in use of pepducin chemistry to develop and commercialize novel therapeutics that uniquely target the critical intracellular domains of cell surface receptors, the firm's proprietary, cell-penetrating PAR2 pepducin technology is designed to advance a new generation of drugs to effectively treat inflammatory and fibrotic diseases. With facilities in Boston and Lexington MA., Oasis is currently developing a drug (PZ-235) - a protease-activated receptor-2 (PAR2) inhibitor. Development of the drug is an ongoing collaboration between Oasis and Tufts Medical Center in Boston, Massachusetts. Inhibiting PAR2 is thought to be a potential treatment for nonalcoholic steatohepatitis; blocking the actions of PAR2, PZ-235 is judged likely to prevent cirrhosis of the liver.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Athan Kuliopulos -- Founder and CEO

  John Amedio -- VP Chemistry, Manufacturing & Control

  Lidija Covic -- Chief Scientific Officer

  Ana Minnick -- VP Regulatory & Pharmacology

  Dana Minnick -- VP Regulatory & Pharmacology

Company News

There are no news available.